New BIND Study Highlights Financial Burden of Neuromuscular Disorders
Celebrating the Publication of the BIND Study
We are delighted to share that the BIND study, “Financial Toxicity and Its Determinants in Individuals Living With Neuromuscular Diseases,” has been published in Neurology (2025). This is the first of its kind in Canada to document the true costs of living with neuromuscular diseases
This achievement reflects the strength of collaboration. Under the leadership of Dr. Jodi Warman-Chardon, the study was made possible through the contributions of Dr. Alyssa Grant, our members Dr. Ian Smith and Dr. Lola Lessard, and our investigators Dr. Homira Osman, Dr. Hanns Lochmüller, Dr. Hugh McMillan, Dr. Gerald Pfeffer, Dr. Lawrence Korngut, Dr. Cynthia Gagnon, Stacey Lintern, Dr. Kathryn Selby and Dr. Kednapa Thavorn
Drawing on the voices of more than 1,400 Canadians, the study reveals the widespread financial pressures faced by individuals with neuromuscular disorders and their caregivers. Among the key findings:
- Three-quarters of participants reported incomes below the national median, largely due to reduced employment.
- 70% of respondents experienced moderate to severe financial strain—worse than levels reported for many common chronic conditions, including cancer.
- Caregivers consistently reported significant financial burden.
- Financial hardship was particularly pronounced among those with lower incomes or education, members of racialized communities, individuals unable to work, students, early retirees, and those living with autoimmune myopathies, spinal muscular atrophy, or limb-girdle muscular dystrophy.
The BIND study was supported by the Canadian Institutes of Health Research (CIHR), with additional support from Muscular Dystrophy Canada (MDC) and our research network.
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.